FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection By Ogkologos - January 14, 2026 295 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the PALOMA-3 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Doctors Seem To Be Biased Against Unmarried Cancer Patients, Offer Them... November 26, 2019 How Clinical Trials Can Lead to Life-Saving Treatment: The TAPUR Trial... October 12, 2023 A Favourable Benefit-Risk Profile for Taletrectinib in TKI-Naїve and Crizotinib-Pretreated Patients... July 24, 2024 October is National Dental Hygiene Month October 1, 2020 Load more HOT NEWS COVID Vaccine Basics for Cancer Patients Daughter And Her Terminally Ill Dad Go On Bucket List Adventures... Cancer in My Community: Caring for the Whole Patient in Brazil Will Ponsegromab Be a Game Changer for Cancer Cachexia?
